PureTech Health plc is reaping the benefits of the excitement surrounding the schizophrenia candidate KarXT from Karuna Therapeutics, Inc., one of the companies it founded, with the sale of royalty rights that could bring in up to $500m to advance its own pipeline.
It has been a very busy week for Karuna which kicked off with a second set of positive Phase III...








